Home›Trial›NCT07176689
NCT07176689Phase 4RECRUITING

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Study Summary

This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.

Conditions
Desmoid TumorAggressive Fibromatosis
Interventions / Drugs
Nirogacestat
View on ClinicalTrials.gov ↗
Sponsor
SWTX
SpringWorks Therapeutics
Rare Oncology
D40/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorSpringWorks Therapeutics, Inc.
Data Retrieved2026-04-11 04:28:29.597186+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 50 participants
Sponsor Catalyst Profile

SpringWorks Therapeutics (SWTX) is the sponsoring company for this trial. BiotechSign currently grades this company D (40/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

SWTX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.